STAT3 is aberrantly hyperactive in most malignant cancers, including CRC, and is generally associated with a poor clinical prognosis, suggesting that STAT3 is an important molecular target for CRC therapy (Wang and Sun, 2014; Johnson et al., 2018). The gene discussed is STAT3; the disease is cancer.